Диагностическая значимость определения нейроспецифических белков в крови у больных с менингиомами

Abstract

The purpose was to study the diagnostic value of the content of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF) in patients with meningiomas before and after surgery. Material and methods. The study involved 70 patients with meningiomas and 62 healthy people. The examination of the patients included clinical and neurological examination, determination of BDNF and GDNF (R&D Systems, USA) content in blood plasma using enzyme immunoassay performed before the surgery and 5–6 days after meningioma surgery. The totality of meningioma removal was determined intraoperatively, which was then confirmed by control neuroimaging a day after the operation. Results. BDNF level less than 2038,6 PG/ml allows diagnosing the characteristic of meningiomas changes with a sensitivity of 88% and a specificity of 44%. GDNF level more than 3.1 PG/ml allows diagnosing the meningioma-related changes in the brain with sensitivity of 84% and specificity of 51%. The plasma level of BDNF in patients after subtotal removal of meningioma on 5–6 days after surgery significantly increased, compared with the preoperative value, p = 0,01. The plasma concentration of GDNF in patients with meningiomas after radical removal of the tumor significantly decreased compared to its preoperative lever, p = 0,01. Conclusion. To summarize, our data show that none of the investigated markers is suitable to substitute histological diagnosis. However, measurement of circulating BDNF and GDNF before and after surgery may be a support to diagnose the totality of meningioma removal.